References
- Brandon EF, Raap CD, Meijerman I, Beijnen JH, Schellens JH. (2003). An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol 189:233–46.
- Donato MT, Castell JV. (2003). Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. Clin Pharmacokinet 42:153–78.
- Floby E, Briem S, Terelius Y, Sohlenius-Sternbeck A-K. (2004). Use of a cocktail of probe substrates for drug-metabolizing enzymes for the assessment of the metabolic capacity of hepatocyte preparations. Xenobiotica 34:949–59.
- Funk C. (2008). The role of hepatic transporters in drug elimination. Exp Opinion Drug Metab Toxicol 4:363–79.
- Hallifax D, Galetin A, Houston JB. (2008). Prediction of metabolic clearance using fresh human hepatocytes: comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines. Xenobiotica 38:353–67.
- Hewitt NJ, Lechon MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, Guillouzo A, Tuschl G, Li AP, LeCluyse E, Groothuis GM, Hengstler JG. (2007). Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159–234.
- Houle R, Raoul J, Levesque JF, Pang KS, Nicoll-Griffith DA, Silva JA. (2003). Retention of transporter activities in cryopreserved, isolated rat hepatocytes. Drug Metab Dispos 31:447–51.
- Houston JB. (1994). Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469–79.
- LeCluyse EL, Alexandre E, Hamilton GA, Viollon-Abadie C, Coon DJ, Jolley S, Richert L. (2005). Isolation and culture of primary human hepatocytes. Meth Mol Biol 290:207–29.
- Li AP. (2007). Human hepatocytes: isolation, cryopreservation and applications in drug development. Chem-Biol Interact 168:16–29.
- Li AP, Lu C, Brent JA, Pham C, Fackett A, Ruegg CE, Silber PM. (1999). Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug–drug interaction potential. Chem Biol Interact 121:17–35.
- Li AP, Maurel P, Gomez-Lechon MJ, Cheng LC, and Jurima-Romet M. (1997). Preclinical evaluation of drug–drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chem-Biol Interact 107:5–16.
- McGinnity DF, Soars MG, Urbanowicz RA, Riley RJ. (2004). Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos 32:1247–53.
- Naritomi Y, Terashita S, Kagayama A, Sugiyama Y. (2003). Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos 31:580–8.
- Soars MG, Grime K, Sproston JL, Webborn PJ, Riley RJ. (2007a). Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. Drug Metab Dispos 35:859–65.
- Soars MG, McGinnity DF, Grime K, Riley RJ. (2007b). The pivotal role of hepatocytes in drug discovery. Chem-Biol Interact 168:2–15.
- Sohlenius-Sternbeck A-K, Schmidt S. (2005). Impaired glutathione-conjugating capacity by cryopreserved human and rat hepatocytes. Xenobiotica 35:727–36.
- Stevenson DJ, Morgan C, McLellan LI, Grant MH. (2007). Reduced glutathione levels and expression of the enzymes of glutathione synthesis in cryopreserved hepatocyte monolayer cultures. Toxicol in Vitro 21:527–32.
- Swales NJ, Utesch D. (1998). Metabolic activity of fresh and cryopreserved dog hepatocyte suspensions. Xenobiotica 28:937–48.